PROGRESS Trial Reports Edwards TAVR Superior to Clinical Surveillance
The PROGRESS trial reports Edwards TAVR was superior to clinical surveillance for moderate aortic stenosis patients with at-risk features.
Story updates
05:40:04 PM UTC
SquawkNews
TAVR delivered more than 30% reduction in the composite endpoint of death or heart failure event as
05:40:30 PM UTC
SquawkNews
In the 744-patient PROGRESS Trial, TAVR reduced the two-year composite rate of death or heart failure events by 33% versus clinical surveillance: 16.7% vs. 23.9%. Use for moderate aortic stenosis is investigational.Material DetailsContext by AI AnalystThis is a mid-cycle clinical evidence catalyst…
05:44:26 PM UTC
SquawkNews
PROGRESS met its primary endpoint, with TAVR cutting the 2-year composite of death or heart failure